The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Vector Vaccines Market Research Report 2024
Synopsis
Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier.
In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.
Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
Researchers are working on both bacteria-l and viral-based recombinant vector vaccines for HIV, rabies, and measles.
The global Recombinant Vector Vaccines market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Recombinant Vector Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Vector Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Recombinant Vector Vaccines include SANOFI PASTEUR S.A., Novartis, GSK, CNBG, ChengDa Bio, Changsheng Life, Zhifei, SINOVAC BIOTECH and NuoCheng Bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Recombinant Vector Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Vector Vaccines.
Report Scope
The Recombinant Vector Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Vector Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Vector Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
SANOFI PASTEUR S.A.
Novartis
GSK
CNBG
ChengDa Bio
Changsheng Life
Zhifei
SINOVAC BIOTECH
NuoCheng Bio
Hualan Bio
Kangtai
Segment by Type
Varicella
Influenza
Hepatitis
Pertussis, Diphtheria, tetanus
Pneumococcal
Others
Segment by Application
For Adult
For Child
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Vector Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Vector Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier.
In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.
Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
Researchers are working on both bacteria-l and viral-based recombinant vector vaccines for HIV, rabies, and measles.
The global Recombinant Vector Vaccines market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Recombinant Vector Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Vector Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Recombinant Vector Vaccines include SANOFI PASTEUR S.A., Novartis, GSK, CNBG, ChengDa Bio, Changsheng Life, Zhifei, SINOVAC BIOTECH and NuoCheng Bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Recombinant Vector Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Vector Vaccines.
Report Scope
The Recombinant Vector Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Vector Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Vector Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
SANOFI PASTEUR S.A.
Novartis
GSK
CNBG
ChengDa Bio
Changsheng Life
Zhifei
SINOVAC BIOTECH
NuoCheng Bio
Hualan Bio
Kangtai
Segment by Type
Varicella
Influenza
Hepatitis
Pertussis, Diphtheria, tetanus
Pneumococcal
Others
Segment by Application
For Adult
For Child
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Vector Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Vector Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Recombinant Vector Vaccines Market Overview
1.1 Product Overview and Scope of Recombinant Vector Vaccines
1.2 Recombinant Vector Vaccines Segment by Type
1.2.1 Global Recombinant Vector Vaccines Market Value Comparison by Type (2024-2030)
1.2.2 Varicella
1.2.3 Influenza
1.2.4 Hepatitis
1.2.5 Pertussis, Diphtheria, tetanus
1.2.6 Pneumococcal
1.2.7 Others
1.3 Recombinant Vector Vaccines Segment by Application
1.3.1 Global Recombinant Vector Vaccines Market Value by Application: (2024-2030)
1.3.2 For Adult
1.3.3 For Child
1.4 Global Recombinant Vector Vaccines Market Size Estimates and Forecasts
1.4.1 Global Recombinant Vector Vaccines Revenue 2019-2030
1.4.2 Global Recombinant Vector Vaccines Sales 2019-2030
1.4.3 Global Recombinant Vector Vaccines Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Vector Vaccines Market Competition by Manufacturers
2.1 Global Recombinant Vector Vaccines Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Vector Vaccines Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Vector Vaccines Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Vector Vaccines Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Vector Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Vector Vaccines, Product Type & Application
2.7 Recombinant Vector Vaccines Market Competitive Situation and Trends
2.7.1 Recombinant Vector Vaccines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Vector Vaccines Players Market Share by Revenue
2.7.3 Global Recombinant Vector Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Vector Vaccines Retrospective Market Scenario by Region
3.1 Global Recombinant Vector Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Vector Vaccines Global Recombinant Vector Vaccines Sales by Region: 2019-2030
3.2.1 Global Recombinant Vector Vaccines Sales by Region: 2019-2024
3.2.2 Global Recombinant Vector Vaccines Sales by Region: 2025-2030
3.3 Global Recombinant Vector Vaccines Global Recombinant Vector Vaccines Revenue by Region: 2019-2030
3.3.1 Global Recombinant Vector Vaccines Revenue by Region: 2019-2024
3.3.2 Global Recombinant Vector Vaccines Revenue by Region: 2025-2030
3.4 North America Recombinant Vector Vaccines Market Facts & Figures by Country
3.4.1 North America Recombinant Vector Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Vector Vaccines Sales by Country (2019-2030)
3.4.3 North America Recombinant Vector Vaccines Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Vector Vaccines Market Facts & Figures by Country
3.5.1 Europe Recombinant Vector Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Vector Vaccines Sales by Country (2019-2030)
3.5.3 Europe Recombinant Vector Vaccines Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Vector Vaccines Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Vector Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Vector Vaccines Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Vector Vaccines Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Vector Vaccines Market Facts & Figures by Country
3.7.1 Latin America Recombinant Vector Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Vector Vaccines Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Vector Vaccines Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Vector Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Vector Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Vector Vaccines Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Vector Vaccines Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Vector Vaccines Sales by Type (2019-2030)
4.1.1 Global Recombinant Vector Vaccines Sales by Type (2019-2024)
4.1.2 Global Recombinant Vector Vaccines Sales by Type (2025-2030)
4.1.3 Global Recombinant Vector Vaccines Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Vector Vaccines Revenue by Type (2019-2030)
4.2.1 Global Recombinant Vector Vaccines Revenue by Type (2019-2024)
4.2.2 Global Recombinant Vector Vaccines Revenue by Type (2025-2030)
4.2.3 Global Recombinant Vector Vaccines Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Vector Vaccines Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Vector Vaccines Sales by Application (2019-2030)
5.1.1 Global Recombinant Vector Vaccines Sales by Application (2019-2024)
5.1.2 Global Recombinant Vector Vaccines Sales by Application (2025-2030)
5.1.3 Global Recombinant Vector Vaccines Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Vector Vaccines Revenue by Application (2019-2030)
5.2.1 Global Recombinant Vector Vaccines Revenue by Application (2019-2024)
5.2.2 Global Recombinant Vector Vaccines Revenue by Application (2025-2030)
5.2.3 Global Recombinant Vector Vaccines Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Vector Vaccines Price by Application (2019-2030)
6 Key Companies Profiled
6.1 SANOFI PASTEUR S.A.
6.1.1 SANOFI PASTEUR S.A. Corporation Information
6.1.2 SANOFI PASTEUR S.A. Description and Business Overview
6.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio
6.1.5 SANOFI PASTEUR S.A. Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Recombinant Vector Vaccines Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 GSK
6.3.1 GSK Corporation Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GSK Recombinant Vector Vaccines Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 CNBG
6.4.1 CNBG Corporation Information
6.4.2 CNBG Description and Business Overview
6.4.3 CNBG Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CNBG Recombinant Vector Vaccines Product Portfolio
6.4.5 CNBG Recent Developments/Updates
6.5 ChengDa Bio
6.5.1 ChengDa Bio Corporation Information
6.5.2 ChengDa Bio Description and Business Overview
6.5.3 ChengDa Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.5.4 ChengDa Bio Recombinant Vector Vaccines Product Portfolio
6.5.5 ChengDa Bio Recent Developments/Updates
6.6 Changsheng Life
6.6.1 Changsheng Life Corporation Information
6.6.2 Changsheng Life Description and Business Overview
6.6.3 Changsheng Life Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Changsheng Life Recombinant Vector Vaccines Product Portfolio
6.6.5 Changsheng Life Recent Developments/Updates
6.7 Zhifei
6.6.1 Zhifei Corporation Information
6.6.2 Zhifei Description and Business Overview
6.6.3 Zhifei Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Zhifei Recombinant Vector Vaccines Product Portfolio
6.7.5 Zhifei Recent Developments/Updates
6.8 SINOVAC BIOTECH
6.8.1 SINOVAC BIOTECH Corporation Information
6.8.2 SINOVAC BIOTECH Description and Business Overview
6.8.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.8.4 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio
6.8.5 SINOVAC BIOTECH Recent Developments/Updates
6.9 NuoCheng Bio
6.9.1 NuoCheng Bio Corporation Information
6.9.2 NuoCheng Bio Description and Business Overview
6.9.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.9.4 NuoCheng Bio Recombinant Vector Vaccines Product Portfolio
6.9.5 NuoCheng Bio Recent Developments/Updates
6.10 Hualan Bio
6.10.1 Hualan Bio Corporation Information
6.10.2 Hualan Bio Description and Business Overview
6.10.3 Hualan Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Hualan Bio Recombinant Vector Vaccines Product Portfolio
6.10.5 Hualan Bio Recent Developments/Updates
6.11 Kangtai
6.11.1 Kangtai Corporation Information
6.11.2 Kangtai Recombinant Vector Vaccines Description and Business Overview
6.11.3 Kangtai Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Kangtai Recombinant Vector Vaccines Product Portfolio
6.11.5 Kangtai Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Vector Vaccines Industry Chain Analysis
7.2 Recombinant Vector Vaccines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Vector Vaccines Production Mode & Process
7.4 Recombinant Vector Vaccines Sales and Marketing
7.4.1 Recombinant Vector Vaccines Sales Channels
7.4.2 Recombinant Vector Vaccines Distributors
7.5 Recombinant Vector Vaccines Customers
8 Recombinant Vector Vaccines Market Dynamics
8.1 Recombinant Vector Vaccines Industry Trends
8.2 Recombinant Vector Vaccines Market Drivers
8.3 Recombinant Vector Vaccines Market Challenges
8.4 Recombinant Vector Vaccines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
